FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

Arizona Attorney General Kris Mayes says the pharmaceutical company GlaxoSmithKline manipulated patents to reduce ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

Recent developments illustrate dynamic shifts in the healthcare sector. Trump's spending bill is anticipated to challenge ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...